The latest price target for Indaptus Therapeutics (NASDAQ:INDP) was reported by Maxim Group on November 13, 2024. The analyst firm set a price target for $5.00 expecting INDP to rise to within 12 months (a possible 419.75% upside). 4 analyst firms have reported ratings in the last year.

The latest analyst rating for Indaptus Therapeutics (NASDAQ:INDP) was provided by Maxim Group, and Indaptus Therapeutics maintained their buy rating.

There is no last upgrade for Indaptus Therapeutics

There is no last downgrade for Indaptus Therapeutics.

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Indaptus Therapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Indaptus Therapeutics was filed on November 13, 2024 so you should expect the next rating to be made available sometime around November 13, 2025.

While ratings are subjective and will change, the latest Indaptus Therapeutics (INDP) rating was a maintained with a price target of $8.00 to $5.00. The current price Indaptus Therapeutics (INDP) is trading at is $0.96, which is out of the analyst’s predicted range.